AWARD-6 is a randomized, open, parallel-grouped, multicenter, phase 3, non-inferiority study comparing the safety and efficacy of weekly DUL and daily LIR in patients with uncontrolled T2DM treated with metformin
This thorough assessment ensures that we understand your unique needs and can tailor our treatments accordingly
Given its progressive nature, type 2 diabetes is not only associated with high morbidity but also with serious long-term complications, such as cardiovascular disease, neuropathy, nephropathy, and retinopathy, which further exacerbate patient outcomes and healthcare costs [1, 2]
27 Pilato, M
Guidelines on management of low-grade gliomas: report of an EFNSEANO Task Force
However, most patients adjust well to the treatment after starting at a lower dose